Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-Fluoro-L-DOPA PET Imaging for Congenital Hyperinsulinism
NCT04205604Phase 2Recruiting
- Start
- Nov 2016
- Primary completion
- Dec 2026
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Fluorodopa F 18 in congenital hyperinsulinism (HI). Primary endpoints: Sensitivity of Imaging at 4 weeks and Accuracy of Imaging at 4 weeks. Started Nov 2016; status: recruiting.
02
Drugs
Fluorodopa F 18
03
Conditions
congenital hyperinsulinism (HI)
Beyond the preview
Go deeper on NCT04205604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04205604.